Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham Pawelec

Showing results (321-330 of 349) with videos related to

Pageof 35
Sort By:
Frontiers in Immunology|July 25, 2022
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 BlockadeAndrea Gaißler, Trine Sundebo Meldgaard, Christina Heeke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2014
Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanomaHenning Zelba, Benjamin Weide, Alexander Martens, et al.
Immunity & Ageing : I & A|September 9, 2010
Immunosenescence and Cytomegalovirus: where do we stand after a decade?Graham Pawelec, Arne Akbar, Peter Beverley, et al.
Immunity & Ageing : I & A|June 8, 2023
Aging and chronic inflammation: highlights from a multidisciplinary workshopDanay Saavedra, Ana Laura Añé-Kourí, Nir Barzilai, et al.
Journal of Translational Medicine|November 7, 2012
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapiesAdrian Bot, Mark Ahn, Marnix Bosch, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2017
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsKilian Wistuba-Hamprecht, Alexander Martens, Florian Heubach, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.
Journal for Immunotherapy of Cancer|December 22, 2021
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapyJonas Bochem, Henning Zelba, Janine Spreuer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, et al.
Nature Medicine|July 3, 2026
Immune aging biomarkers for clinical trialsAndrea Cipriano, Jamie Justice, Jesse R Poganik, et al.
Pageof 35

Showing results (321-330 of 349) with videos related to

Sort By:
Pageof 35
Frontiers in Immunology|July 25, 2022
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 BlockadeAndrea Gaißler, Trine Sundebo Meldgaard, Christina Heeke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2014
Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanomaHenning Zelba, Benjamin Weide, Alexander Martens, et al.
Immunity & Ageing : I & A|September 9, 2010
Immunosenescence and Cytomegalovirus: where do we stand after a decade?Graham Pawelec, Arne Akbar, Peter Beverley, et al.
Immunity & Ageing : I & A|June 8, 2023
Aging and chronic inflammation: highlights from a multidisciplinary workshopDanay Saavedra, Ana Laura Añé-Kourí, Nir Barzilai, et al.
Journal of Translational Medicine|November 7, 2012
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapiesAdrian Bot, Mark Ahn, Marnix Bosch, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2017
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsKilian Wistuba-Hamprecht, Alexander Martens, Florian Heubach, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.
Journal for Immunotherapy of Cancer|December 22, 2021
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapyJonas Bochem, Henning Zelba, Janine Spreuer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, et al.
Nature Medicine|July 3, 2026
Immune aging biomarkers for clinical trialsAndrea Cipriano, Jamie Justice, Jesse R Poganik, et al.
Pageof 35